Kieso R A, Fox-Eastham K, Kerber R E
Department of Internal Medicine, University of Iowa College of Medicine, Iowa City.
Am Heart J. 1991 Mar;121(3 Pt 1):834-9. doi: 10.1016/0002-8703(91)90196-o.
Sequences of ventricular fibrillation-defibrillation cause transient hypertension; we hypothesized that this "adrenergic overshoot" might be blunted by the functional antiadrenergic effect of the calcium channel blocking drug nisoldipine, with a potentially beneficial reduction in myocardial oxygen requirements. However, other calcium channel blocking drugs have been shown to reduce shock success for defibrillation, a deleterious effect. Thus the purposes of this study were to assess the effect of nisoldipine on the hemodynamic responses to the sequences of ventricular fibrillation-defibrillation, and its effect on the energy requirements for defibrillation. In 16 dogs we administered intravenous nisoldipine (1 microgram/kg bolus followed by an infusion of 0.075 to 0.50 microgram/kg/min) to lower mean blood pressure 10% and 20% below baseline. Ventricular fibrillation was induced electrically, and shocks of varying energy levels (30, 50, and 100 joules) were administered to determine defibrillation energy requirements. Heart rates and blood pressures were recorded up to 3 minutes after each shock to determine hemodynamic responses. Measurements were made before nisoldipine administration and again at the two levels of drug-induced blood pressure decline. We found that the usual systolic blood pressure "overshoot" after defibrillation (typically maximum at 15 to 30 seconds after shocks) was significantly blunted after nisoldipine administration (p less than 0.05). Heart rate slowing after defibrillation (a cholinergic response) was not affected. Nisoldipine did not alter shock success rates, which varied from 12 +/- 7%SE at 30 joules to 68 +/- 12% at 100 joules. Thus nisoldipine blunted the "adrenergic overshoot" of systolic blood pressure following defibrillation, a potentially beneficial effect, without altering the energy requirements for transthoracic defibrillation.
室颤-除颤序列会导致短暂性高血压;我们推测,钙通道阻滞剂尼索地平的功能性抗肾上腺素能作用可能会减弱这种“肾上腺素能超射”,从而有可能有益地降低心肌需氧量。然而,其他钙通道阻滞剂已被证明会降低除颤的电击成功率,这是一种有害作用。因此,本研究的目的是评估尼索地平对室颤-除颤序列血流动力学反应的影响,及其对除颤能量需求的影响。在16只犬中,我们静脉给予尼索地平(1微克/千克推注,随后以0.075至0.50微克/千克/分钟的速度输注),使平均血压比基线降低10%和20%。通过电刺激诱发室颤,并给予不同能量水平(30、50和100焦耳)的电击以确定除颤能量需求。在每次电击后记录心率和血压长达3分钟,以确定血流动力学反应。在给予尼索地平之前以及在药物诱导的血压下降的两个水平时再次进行测量。我们发现,尼索地平给药后,除颤后通常出现的收缩压“超射”(通常在电击后15至30秒达到最大值)明显减弱(p<0.05)。除颤后心率减慢(一种胆碱能反应)未受影响。尼索地平未改变电击成功率,电击成功率在30焦耳时为12±7%SE,在100焦耳时为68±12%。因此,尼索地平减弱了除颤后收缩压的“肾上腺素能超射”,这是一种潜在的有益作用,同时未改变经胸除颤的能量需求。